• Miao-Nan Li, Bing-Wei Bao, Ding Si-Yu, Ji Chun-Fei, Shi Xiao-Jun, Gao Da-Sheng, Gao Qin, and Wang Hong-Ju.
• From the Department of Cardiovascular Disease (Li, Bao, Ding, Ji, Shi, D-S. Gao, Q. Gao, Wang), The First Affiliated Hospital of Bengbu Medical College, and from the Department of Physiology (Q. Gao), Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Bengbu Medical College, Bengbu, China.
• Saudi Med J. 2022 Oct 1; 43 (10): 110311101103-1110.

ObjectivesTo investigate the correlation between plasma glutathione peroxidase 4 (GPX4) and N-acetyl-neuraminic acid (Neu5Ac) with clinical risk stratification and outcomes of acute coronary syndrome (ACS) patients.MethodsBetween October 2018 and July 2019, 413 patients that were scheduled for coronary angiography were enrolled in this prospective study at the First Affiliated Hospital of Bengbu Medical College, Bengbu, China. Patients were divided into control and ACS groups. Patients with ACS were divided into 3 risk levels based on their thrombolysis in myocardial infarction risk score. After discharge, ACS patients were followed for the incidence of major adverse cardiac events (MACEs). For the analysis of cumulative endpoint event occurrences, the Kaplan-Meier method was applied.ResultsThe ACS group had lower plasma GPX4 but higher Neu5Ac levels than the control group. There was a greater increase in plasma Neu5Ac in the high-risk group when compared with the medium-risk and low-risk groups, while GPX4 levels were higher in the low-risk group. The MACEs group had higher plasma Neu5Ac but lower GPX4 levels than the non-MACEs group. The plasma Neu5Ac was an independent risk factor but GPX4 was a protective factor for MACEs.ConclusionGlutathione peroxidase 4 and Neu5Ac levels in plasma can be used to diagnose, stratify risks, and predict long-term outcomes in patients with ACS.Copyright: © Saudi Medical Journal.

13 keywords...

hide…